In last trading session, Bristol-Myers Squibb Company (NYSE:BMY) saw 4,936,256 shares changing hands with its beta currently measuring 0.71. Company’s recent per share price level of $57.2 trading at -$0.8 or -1.41% at recent trade assigns it a market valuation of $129.79 Billion. That current price of BMY’s stock is at a discount of -19.48% from its 52-week high price of $68.34 and is indicating a premium of 25.73% from its 52-week low price of $42.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 19.95 Million shares which gives us an average trading volume of 16.53 Million if we extend that period to 3-months.

For Bristol-Myers Squibb Company (BMY), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 1.9. Splitting up the data highlights that, out of 16 analysts covering the stock, none rated the stock as a Sell while 2 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 9 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $1.49 in the current quarter.

Bristol-Myers Squibb Company (NYSE:BMY) trade information

In the face of being in the red today for losing -1.68%, in the last five days BMY remained trading in the green while hitting it’s week-highest on Tuesday, Jun 23 when the stock touched $59.10- price level, adding 2.7% to its value on the day. Bristol-Myers Squibb Company’s shares saw a change of -10.41% in year-to-date performance and have moved 1.94% in past 5-day. Bristol-Myers Squibb Company (NYSE:BMY) showed a performance of -4.67% in past 30-days. Number of shares sold short was 30.59 Million shares which calculate 1.85 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $71.91 to the stock, which implies a rise of 25.72% to its current value. Analysts have been projecting $62 as a low price target for the stock while placing it at a high target of $81. It follows that stock’s current price would jump +41.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of 8.39% for stock’s current value.

Bristol-Myers Squibb Company (BMY) estimates and forecasts

Statistics highlight that Bristol-Myers Squibb Company is scoring comparatively higher than the scores of other players of the relevant industry. The company lessened -7.88% of value to its shares in past 6 months, showing an annual growth rate of 30.92% while that of industry is 7.9. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 26.3% in the current quarter and calculating 29.1% increase in the next quarter. This year revenue growth is estimated to rise 60% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $9.91 Billion for the same. And 7 analysts are in estimates of company making revenue of $10.31 Billion in the next quarter that will end in September 01, 2020. Company posted $6.27 Billion and $6.01 Billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 58% while estimating it to be 71.7% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.9% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -33.9% while estimates for its earnings growth in next 5 years are of 17.9%

BMY Dividends

Bristol-Myers Squibb Company is more likely to be releasing its next quarterly report between August 06 and August 06, 2020, and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 3.09%, the share has a forward dividend of 1.8 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 2.73%.